Verona pharma reports second quarter 2023 financial results and provides corporate update

Nda submitted to us fda for ensifentrine for maintenance treatment of copd phase 3 enhance data published in the american journal of respiratory and critical care medicine strong balance sheet to support commercial launch preparations conference call today at 9:00 a.m. edt / 2:00 p.m.
VRNA Ratings Summary
VRNA Quant Ranking